文献速递泌尿男性生殖肿瘤

原发性肾细胞癌立体定向消融体部放疗后5年结局:IROCK国际肾放射外科联盟个体患者数据Meta分析

5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
PubMed 文献 · Lancet Oncol · 2022-11-16

该个体患者数据Meta分析纳入5国12家机构190例接受SABR的原发性肾细胞癌患者,中位随访5.0年,5年局部失败累积发生率为5.5%(95%CI 2.8-9.5),单次分割局部失败少于多次分割(Gray's p=0.020),无3级毒性或治疗相关死亡。

要点

  • 5年局部失败累积发生率为5.5%(95%CI 2.8-9.5),单次分割SABR局部失败少于多次分割(Gray's p=0.020)。
  • 无3级毒性或治疗相关死亡;1例(1%)出现急性4级十二指肠溃疡和晚期4级胃炎。
  • SABR后5年eGFR较基线下降14.2 mL/min per 1.73 m²(IQR 5.4-22.5),7例(4%)需透析。

核心结论

  • SABR对原发性肾细胞癌患者具有长期有效性和安全性。
  • 单次分割SABR可能比多次分割产生更少的局部失败,但需要随机试验的进一步证据来阐明最佳治疗分割方案。
  • 这些成熟数据进一步支持将肾SABR作为不愿或不适于手术患者的治疗选择。

研究设计与样本

  • 本研究为个体患者数据Meta分析,纳入5个国家(澳大利亚、加拿大、德国、日本和美国)12家机构接受SABR的原发性肾细胞癌患者。
  • 纳入标准为随访至少2年、年龄18岁及以上、任何体能状态、无既往局部治疗;排除转移性肾细胞癌或上尿路尿路上皮癌患者。
  • SABR为单次或多次分割,每次分割剂量大于5 Gy。
  • 共190例患者于2007年3月23日至2018年9月20日期间接受SABR;单次分割81例(43%),多次分割109例(57%)。
  • 中位随访5.0年(IQR 3.4-6.8);139例(73%)为男性,51例(27%)为女性;中位年龄73.6岁(IQR 66.2-82.0);中位肿瘤直径4.0 cm(IQR 2.8-4.9)。

主要发现

  • 128例有可手术性详情的患者中,96例(75%)被转诊泌尿科医生判定为不可手术;190例中56例(29%)为孤立肾。
  • 中位基线eGFR为60.0 mL/min per 1.73 m²(IQR 42.0-76.0),SABR后5年下降14.2 mL/min per 1.73 m²(IQR 5.4-22.5);7例(4%)SABR后需透析。
  • 5年局部失败累积发生率总体为5.5%(95%CI 2.8-9.5),单次分割SABR局部失败少于多次分割(Gray's p=0.020)。
  • 无3级毒性反应或治疗相关死亡;1例(1%)患者出现急性4级十二指肠溃疡和晚期4级胃炎。

临床怎么用

  • 作者认为,SABR对原发性肾细胞癌患者具有长期有效性和安全性。
  • 作者认为,单次分割SABR可能比多次分割产生更少的局部失败,但需要随机试验的进一步证据来阐明最佳治疗分割方案。
  • 作者认为,这些成熟数据进一步支持将肾SABR作为不愿或不适于手术患者的治疗选择。

局限性

  • 单次分割SABR可能比多次分割产生更少的局部失败,但需要随机试验的进一步证据来阐明最佳治疗分割方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive treatment option for primary renal cell carcinoma, for which long-term data are awaited. The primary aim of this study was to report on long-term efficacy and safety of SABR for localised renal cell carcinoma. METHODS: This study was an individual patient data meta-analysis, for which patients undergoing SABR for primary renal cell carcinoma across 12 institutions in five countries (Australia, Canada, Germany, Japan, and the USA) were eligible. Eligible patients had at least 2 years of follow-up, were aged 18 years or older, had any performance status, and had no previous local therapy. Patients with metastatic renal cell carcinoma or upper-tract urothelial carcinoma were excluded. SABR was delivered as a single or multiple fractions of greater than 5 Gy. The primary endpoint was investigator-assessed local failure per the Response Evaluation Criteria in Solid Tumours version 1.1, and was evaluated using cumulative incidence functions. FINDINGS: 190 patients received SABR between March 23, 2007, and Sept 20, 2018. Single-fraction SABR was delivered in 81 (43%) patients and multifraction SABR was delivered in 109 (57%) patients. Median follow-up was 5·0 years (IQR 3·4-6·8). 139 (73%) patients were men, and 51 (27%) were women. Median age was 73·6 years (IQR 66·2-82·0). Median tumour diameter was 4·0 cm (IQR 2·8-4·9). 96 (75%) of 128 patients with available operability details were deemed inoperable by the referring urologist. 56 (29%) of 190 patients had a solitary kidney. Median baseline estimated glomerular filtration rate (eGFR) was 60·0 mL/min per 1·73 m2 (IQR 42·0-76·0) and decreased by 14·2 mL/min per 1·73 m2 (IQR 5·4-22·5) by 5 years post-SABR. Seven (4%) patients required dialysis post-SABR. The cumulative incidence of local failure at 5 years was 5·5% (95% CI 2·8-9·5) overall, with single-fraction SABR yielding fewer local failures than multifraction (Gray's p=0·020). There were no grade 3 toxic effects or treatment-related deaths. One (1%) patient developed an acute grade 4 duodenal ulcer and late grade 4 gastritis. INTERPRETATION: SABR is effective and safe in the long term for patients with primary renal cell carcinoma. Single-fraction SABR might yield less local failure than multifraction, but further evidence from randomised trials is needed to elucidate optimal treatment schedules. These mature data lend further support for renal SABR as a treatment option for patients unwilling or unfit to undergo surgery. FUNDING: None.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Siva S, Ali M, Correa RJM, et al. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Lancet Oncol. 2022. PMID: 36400098. doi:10.1016/S1470-2045(22)00656-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。